NCT04947241View on ClinicalTrials.gov

Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

January 15, 2026

Study Completion Date

January 15, 2026

Conditions

Locally Advanced Head and Neck Squamous Cell CarcinomaNeoadjuvant Therapy

Interventions

DRUG

PD-1 inhibitor+ Gemcitabine + Cisplatin

"Before surgery, patients will receive therapy as follows:~PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles"

Trial Locations (1)

Unknown

RECRUITING

Fifth Affilliated Hospital of Sun Yat-sen University, Zhuhai

All Listed Sponsors

lead

Fifth Affiliated Hospital, Sun Yat-Sen University

OTHER

NCT04947241 - Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC | Biotech Hunter | Biotech Hunter